Diaceutics (DXRX) Trading Update summary

Financial performance and growth

• Revenue increased 39% on a constant currency basis to £32.2 million in FY 2024, with a 3-year CAGR of 32%.

• Adjusted EBITDA expected to be marginally ahead of analyst consensus estimates.

• Annual Recurring Revenue (ARR) grew 23% to £16.8 million, with recurring revenues making up 55% of total revenue.

• Order book at year-end was £24.9 million, with £17.7 million expected to be realised within one year, up 44%.

• Cash position at year-end was £12.7 million, supporting ongoing investment and growth.

Commercial momentum and customer engagement

• Secured three new multi-year enterprise-wide engagements, bringing the total to seven, with ARR from these at £10.6 million.

• Number of customer therapeutic brands increased 23% to 85, and total customers rose 18% to 52.

• Working with 18 of the top 20 global pharma companies across 56 therapeutic brands.

• Launched PMx solution and secured first commercial contract as a promotional partner for a breakthrough oncology precision medicine in the US.

• Introduced Pathology Engagement Liaison service and won first major customer contract.

Strategic initiatives and outlook

• Opened US headquarters in January 2025 and increased US sales presence.

• Accelerated investment strategy is delivering faster-than-planned commercial success.

• Precision medicine market is expanding, with 48 new therapeutic brands receiving FDA approval in 2024.

• Enhanced technologies across the platform are driving operational leverage.

• Board confident in achieving growth and profitability targets for 2025.